KN026 plus chemo for HER2-positive stomach cancer after first treatment failure
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests KN026 together with chemotherapy in people with HER2-positive advanced stomach (or gastro-esophageal junction) cancer that has already grown despite first-line treatment with trastuzumab plus chemotherapy. It may help by targeting HER2 while also using chemotherapy to control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older.
- Your stomach cancer is HER2-positive, based on pathology test results (IHC 3+ or IHC 2+ with a positive ISH test).
- Your cancer has gotten worse after at least one standard treatment plan that included trastuzumab (or you progressed during/within 6 months after that kind of treatment).
- You have at least one measurable (or evaluable) tumor spot on scan, and that area has not had radiation (unless it later clearly progressed after radiation).
- Your overall health is good enough for treatment (ECOG performance status 0–1) and you can live for at least 3 months.
- Your blood counts, liver/kidney tests, and heart pumping strength are within the trial’s limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two new immunotherapy drugs (KN026 and KN046) with or without chemotherapy (XELOX) for people with a specific type of advanced stomach cancer that makes too much HER2 protein. The goal is to see if this combination can shrink tumors or slow the cancer.
This trial tests a new combination of drugs (KN026 plus chemotherapy, with or without KN-046) for people with HER2-positive colorectal or bile duct cancer that has spread. The goal is to see if this treatment can help shrink or control the cancer.
This Phase 3 study tests whether taking KN026 with HB1801 as first treatment works better and is safe for people with HER2-positive breast cancer that has come back or spread. It may help by improving tumor response and delaying progression compared with the study’s treatment plan.
This study tests a combination of drugs (including an investigational drug called KN026) for people with HER2-positive stomach cancer that has not been treated before. The goal is to see if this combination is safe and works better than standard treatment.
This trial tests a combination of two drugs (KN026 and HB1801) given after surgery to prevent breast cancer from coming back in people with HER2-positive breast cancer that had spread to lymph nodes. It aims to improve cure rates with a targeted approach.
This trial tests a new drug called JSKN003 for people with HER2-positive stomach cancer. It may be used as a first treatment for advanced cancer or before surgery for cancer that can be removed. The goal is to see if the drug helps shrink or control the cancer.
Hear when a new Stomach Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.